Johnson & Johnson’s Tecvayli cuts myeloma progression risk 71% as Europe considers much earlier use
European regulators have backed Tecvayli monotherapy after only one prior multiple myeloma treatment, potentially transforming Johnson & Johnson’s BCMA bispecific from a late-line therapy into a much larger second-line franchise.
